Mayne Pharma receives FDA approval of Tolsura treatment

Company News

by Anna Napoli

Mayne Pharma Group (ASX:MYX) has received FDA approval for its Tolsura treatment.

The US Food and Drug Administration has approved Tolsura as a treatment of certain systemic fungal infections in adult patients.

Mayne Pharma will directly commercialize Tolsura and plans to launch in January 2019.

(The US anti-fungal triazole market has a current value of US$600 million.)

The company says after many years of research and development and working closely with key global opinion leaders in infectious disease management, Tolsura represents a major milestone in the Super-BioAvailable drug delivery platform at Mayne Pharma.

Shares in Mayne Pharma Group (ASX:MYX) are 2.8 per cent higher 92 cents


Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.